Current:Home > MyFDA approves a new antibody drug to prevent RSV in babies-Angel Dreamer Wealth Society D1 Reviews & Insights
FDA approves a new antibody drug to prevent RSV in babies
View Date:2025-01-09 19:54:52
This fall, for the first time many babies in the U.S. will be able to get a shot to fend off RSV, a respiratory virus that can cause serious lung disease in infants and young children.
The Food and Drug Administration Monday approved nirsevimab, a single shot of antibodies that was shown in clinical trials to lower the need for medical care from RSV for babies by 70-75%.
Respiratory syncytial virus, or RSV is a viral infection that puts between 58,000 to 80,000 young children in the hospital each year, making it the leading cause of hospitalization among infants in the U.S.
"Today's approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system," said Dr. John Farley, director of the Office of Infectious Diseases in the FDA's Center for Drug Evaluation and Research in a statement.
The treatment can be used to protect infants' during their first RSV season. It is also approved to provide protection during a second season for children up to 2 years old and at risk of severe RSV disease.
Drugmakers AstraZeneca and Sanofi plan to start offering the treatment – which will be marketed as Beyfortus – in time for the upcoming RSV season this fall when respiratory viruses spread widely in much of the country.
They have not announced a price for the product, though a spokesperson for Sanofi says it will be similar to a series of HPV vaccines. For comparison, the recommended series of HPV vaccines for young children costs more than $500 on the commercial market.
In June, a panel of advisers to the FDA had recommended that the agency approve the new antibody drug.
There was unanimous support on the 21-person committee for approving the drug's use in infants ahead of or during their first RSV season. And, in a separate vote, all but two members of the panel supported giving the drug to infants with medical risks through their second RSV season. The FDA ultimately approved it for both uses.
"This is one of the most important infectious diseases in the pediatric population," said Dr. Mary Anne Jackson, a pediatrician at Children's Mercy in Kansas City, Missouri and a voting member.
Members of the committee said the data presented by the drugmakers, AstraZeneca and Sanofi, and the FDA demonstrated that nirsevimab appears to be safe and effective.
According to AstraZeneca's analysis, most RSV hospitalizations could be prevented with use of this drug.
In two clinical trials, involving nearly 3,000 babies, a single shot of the monoclonal antibody reduced the risks of an RSV case that required medical attention by 70-75%, and lowered the risks of hospitalization by 60-80%. High levels of the antibody persisted for at least five months. Side effects, including rashes and fevers, were uncommon and generally mild.
"This is a pathogen that has a substantial impact on the lives of young children, causing significant morbidity and mortality" and limits the ability of children who are sick with other illnesses to get medical care, says Dr. Steven Krug, a pediatric emergency physician and professor at the Northwestern University Feinberg School of Medicine.
Nirsevimab's approval broadens the protection available for babies. Prior to this approval the only existing preventive drug was a monoclonal antibody shot called palivizumab which requires monthly administration and is reserved for babies at high medical risk.
Dr. Marcus Plescia, chief medical officer for the Association of State and Territorial Health Officers, says it may take awhile for parents to warm up to the new drug. "It's recommended very soon after birth," he says. "A lot of parents are a little bit cautious about wanting to give really young children things. So it may take a little bit of time to really build confidence in the monoclonal antibody."
Authorities in the EU approved the antibody last fall, and it is currently being considered for use in several Asian countries.
This antibody shot is one of several new drugs and vaccines in development to protect babies and the elderly from RSV. The FDA is expected to issue a decision on an RSV vaccine to protect newborns that is given to pregnant mothers by late August.
This story has been updated. It originally ran June 8.
veryGood! (5)
Related
- High-scoring night in NBA: Giannis Antetokounmpo explodes for 59, Victor Wembanyama for 50
- Why Brooke Burke Was Tempted to Have “Affair” With Derek Hough During DWTS
- Former Israeli commander says Hamas hostage-taking changes the game, as families search for missing loved ones
- Wayne Brady says opening up about his pansexuality goes part and parcel with mental health: I'm lighter
- Watch: Military dad's emotional return after a year away
- Appeals court upholds order delaying this week’s execution of Texas inmate for deadly carjacking
- Suspects sought in Pennsylvania community center shooting that killed 1, wounded 8
- As poverty spikes, One Warm Coat, Salvation Army coat donations are more important than ever
- Brianna LaPaglia Addresses Zach Bryan's Deafening Silence After Emotional Abuse Allegations
- The story of the drug-running DEA informant behind the databases tracking our lives
Ranking
- The Latin Grammys are almost here for a 25th anniversary celebration
- U.S. working to verify reports of Americans dead or taken hostage in Israel attack, Blinken says
- UAW members reject tentative contract deal with Mack Trucks, will go on strike early Monday
- Michael Chiarello, chef and Food Network star, dies at 61 following allergic reaction: Reports
- Judith Jamison, a dancer both eloquent and elegant, led Ailey troupe to success over two decades
- The story of the drug-running DEA informant behind the databases tracking our lives
- As Republicans split over who will be House speaker, McCarthy positions himself as a de facto leader
- Israel declares war after Hamas attacks, Afghanistan earthquake: 5 Things podcast
Recommendation
-
New Jersey will issue a drought warning after driest October ever and as wildfires rage
-
Punctuation is 'judgey'? Text before calling? How proper cell phone etiquette has changed
-
Lawyer says Black man who died after traffic stop beating had stolen items, hallucinogenic in car
-
Nancy Mace says she supports Jim Jordan for House speaker
-
As CFP rankings punish SEC teams, do we smell bias against this proud and mighty league?
-
Florida settles lawsuit over COVID data, agrees to provide weekly stats to the public
-
I'm a Shopping Editor, and This Is What I'm Buying at Amazon's October Prime Day 2023
-
Former Israeli commander says Hamas hostage-taking changes the game, as families search for missing loved ones